VOQUEZNA TRIPLE PAK

Search documents
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Globenewswire· 2025-08-07 10:59
Core Insights - Phathom Pharmaceuticals reported significant revenue growth in Q2 2025, with net revenues of $39.5 million, up from $7.3 million in Q2 2024, driven by the commercial success of VOQUEZNA products [5][6][11] - The company aims to achieve profitability by 2026, supported by a refined commercial strategy focusing on high-value prescribers and strong prescription trends [2][6][11] Business Highlights - Over 580,000 VOQUEZNA prescriptions have been filled to date, reflecting a 49% increase since the last earnings report [6][7] - Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing a 36% sequential growth from Q1 2025 [7] - The prescriber base has expanded, with over 29,300 unique healthcare providers writing prescriptions, a 24% increase since the last quarterly update [7] Financial Performance - R&D expenses for Q2 2025 were $9.1 million, an increase from $7.4 million in Q2 2024, primarily due to one-time restructuring charges [11] - SG&A expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024, driven by higher personnel-related costs [11] - The net loss for Q2 2025 was $75.8 million, compared to $91.4 million in Q2 2024, with a non-GAAP adjusted net loss of $56.5 million [11][19] Market Position and Strategy - The FDA granted 10-year New Chemical Entity exclusivity for VOQUEZNA, extending market protection until May 2032, which is expected to delay generic competition until at least 2033 [7] - The company has shifted its sales strategy to prioritize gastroenterologists over primary care physicians to enhance prescriber engagement [7] Future Outlook - Phathom expects full-year 2025 revenue to be between $165 million and $175 million, based on strong prescription trends and a refined commercial strategy [6][11] - The company anticipates non-GAAP operating expenses to decrease to less than $60 million in Q3 2025 and less than $55 million in Q4 2025 [11]
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
Globenewswire· 2025-03-31 11:59
FLORHAM PARK, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today a partnership with actor, comedian, and author Kenan Thompson, best known as the longest-running cast member on Saturday Night Live. For the first time ever, Thompson is publicly speaking out about his experience with GERD as part of the GERD IS NO JOKE campaign to raise ...